Home > Healthcare > Pharmaceuticals > Finished Drug Form > Antidepressant Drugs Market

Antidepressant Drugs Market Trends

Report ID: GMI2505
Published Date: Sep 2021
Report Format: PDF

Download Free Sample

Antidepressant Drugs Market Trends

Increasing burden of depression and associated mental health conditions will flourish the demand for antidepressant drugs. As per the World Health Organization, nearly 40 million people are suffering through depressive disorders in Europe that accounts for approximately 4.3% of overall regional population. Moreover, according to the Centers for Disease Control and Prevention, about 16 million adult individuals’ experiences depression in America every year. Such large patient pool will escalate the demand for antidepressant drugs. In addition, as per the World Health Organization, 3 out of 4 people suffering from depression does not receive proper treatment. This represents industry potential to business leaders for the market progression.

Antidepressant drugs market continued to witness revenue growth during COVID-19 pandemic. Emergence of COVID-19 has triggered one of the worst jobs crisis in several sectors that has led to economic instability. Along with economic instability, social isolation with movement restrictions has resulted in depression and anxiety among population.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size of antidepressant drugs was over USD 13.5 billion during 2020 and is expected to witness around 7.2% CAGR up to 2027 with increased access to a large number of products.

Serotonin-norepinephrine reuptake inhibitors (SNRIs) class of drugs held nearly 9% of global antidepressant drugs industry share in 2020 and will grow due to increasing cases of depression and anxiety disorders.

The key types of antidepressant drugs include Serotonin-norepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors {SSRIs} and Tricyclic Antidepressants.

Europe market held more than 25% of revenue share in 2020 and will expand with rising awareness and acceptance of mental disorders and related therapies.

Leading antidepressant drug manufacturers worldwide include Novartis, GlaxoSmithKline, Pfizer, Eli Lilly & Company, Janssen Pharmaceuticals, Bristol-Myers Squibb, Sandoz Inc., Otsuka Pharmaceutical and Sun Pharmaceuticals, among some others.